Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.39 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.39 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17591686 | 0.98 | S1PR1 (0.42) | NAAAEPHX1EPHX2S1PR1S1PR3 | |
| SCHEMBL1460586 | 0.97 | S1PR1 (0.40) | NAAAEPHX1EPHX2S1PR1S1PR3 | |
| SCHEMBL9810899 | 0.92 | CA1 (0.39) | S1PR1S1PR3 | |
| SCHEMBL6243199 | 0.84 | CA1 (0.42) | EPHX1 | |
| SCHEMBL19306981 | 0.83 | CCR2 (0.45) | NAAA | |
| SCHEMBL24820171 | 0.79 | HTT (0.37) | — | |
| SCHEMBL3434503 | 0.76 | CCR2 (0.64) | NAAA | |
| SCHEMBL31488325 | 0.75 | CCR2 (0.63) | NAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL21710335 | 0.73 | CA1 (0.38) | EPHX2 | |
| SCHEMBL10824300 | 0.73 | TSHR (0.38) | NAAAEPHX1EPHX2S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0693932-A4 | METHODS AND COMPOSITIONS FOR INDUCING PHASE SEPARATION OF EPITHELIAL LIPID BILAYERS | CELLEGY PHARMA INC (US) | 2000-06-14 | — | — | EP | claimed |
| EP-0693932-A1 | METHODS AND COMPOSITIONS FOR INDUCING PHASE SEPARATION OF EPITHELIAL LIPID BILAYERS | CELLEGY PHARMACEUTICALS, INC. (US) | 1996-01-31 | — | — | EP | claimed |
| WO-1994021271-A1 | METHODS AND COMPOSITIONS FOR INDUCING PHASE SEPARATION OF EPITHELIAL LIPID BILAYERS | CELLEGY PHARMACEUTICALS, INC. (US) | 1994-09-29 | — | — | WO | claimed |
| US-20140336253-A1 | COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF RIVASTIGMINE | TESA LABTEC GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| EP-2780006-A1 | COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF RIVASTIGMINE | tesa Labtec GmbH (DE) | 2014-09-24 | — | — | EP | disclosed |
| WO-2014111790-A2 | STABLE TRANSDERMAL PHARMACEUTICAL DRUG DELIVERY SYSTEM COMPRISING RIVASTIGMINE | ZYDUS TECHNOLOGIES LIMITED (IN) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014068600-A1 | STABLE TRANSDERMAL PHARMACEUTICAL DRUG DELIVERY SYSTEM COMPRISING DICLOFENAC | ZYDUS TECHNOLOGIES LIMITED (IN) | 2014-05-08 | — | — | WO | disclosed |
| WO-2013072062-A1 | COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF RIVASTIGMINE | LABTEC GMBH (DE) | 2013-05-23 | — | — | WO | disclosed |
| EP-2594261-A1 | Composition for transdermal administration of rivastigmine | Labtec GmbH (DE) | 2013-05-22 | — | — | EP | disclosed |
| US-20120225834-A1 | OCULAR IONTOPHORESIS OF CHARGED MICELLES CONTAINING BIOACTIVE AGENTS | EYEGATE PHARMACEUTICALS, INC. (US) | 2012-09-06 | — | — | US | disclosed |
| EP-2482818-A1 | POSITIVELY-CHARGED POLY (D,L-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES AND FABRICATION METHODS OF THE SAME | Eyegate Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-0465580-A1 | USE OF MONOACYL PHOSPHOGLYCERIDES TO ENHANCE THE CORNEAL PENETRATION OF OPHTHALMIC DRUGS | ALCON LABORATORIES, INC. (US) | 1992-01-15 | — | — | EP | disclosed |
| EP-0444778-A1 | Use of alkyl saccharides to enhance the penetration of drugs | ALCON LABORATORIES, INC. (US) | 1991-09-04 | — | — | EP | disclosed |
| WO-1990011079-A1 | USE OF MONOACYL PHOSPHOGLYCERIDES TO ENHANCE THE CORNEAL PENETRATION OF OPHTHALMIC DRUGS | ALCON LABORATORIES, INC. (US) | 1990-10-04 | — | — | WO | disclosed |
| EP-0315219-A2 | Pharmaceutical compositions | SANDOZ AG (CH) | 1989-05-10 | — | — | EP | disclosed |
| EP-0315217-A2 | Pharmaceutical compositions | SANDOZ AG (CH) | 1989-05-10 | — | — | EP | disclosed |
| EP-0315218-A2 | Pharmaceutical compositions | SANDOZ AG (CH) | 1989-05-10 | — | — | EP | disclosed |
| US-4743588-A | Compositions and methods of enhancing transdermal and transmembrane penetration systemic agents | ALLERGAN PHARMACEUTICALS, INC. (US) | 1988-05-10 | — | — | US | disclosed |
| EP-0164998-A2 | Compositions and methods of enhancing transdermal and transmembrane penetration of topical and systemic agents | ALLERGAN, INC (US) | 1985-12-18 | — | — | EP | disclosed |
| WO-1985003878-A1 | PHARMACEUTICAL COMPOSITIONS | SANDOZ AG (CH) | 1985-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225834-A1 | OCULAR IONTOPHORESIS OF CHARGED MICELLES CONTAINING BIOACTIVE AGENTS | PLA2G2C, PHOSPHO1, ANXA11 | NAAA 1417/4885EPHX1 1392/4885EPHX2 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.